<DOC>
	<DOC>NCT01837082</DOC>
	<brief_summary>The hypothesis to be tested is whether treatment with intravenous iron (ferric carboxymaltose) will improve left-ventricular ejection fraction in patients with heart failure and iron deficiency as determined by cardiac magnetic resonance imaging.</brief_summary>
	<brief_title>Iron in Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Congestive heart failure At least 18 years of age Iron deficiency Dyspnea class II or III according to New York Heart Association Leftventricular ejection fraction â‰¤ 45% Known sensitivity to any of the products to be administered during dosing Immediate need of transfusion Patients presenting with an active infection Thalassaemia Other forms of microcytic anemia not caused by iron deficiency History of acquired iron overload Need for revascularization, STsegment elevation myocardial infarction or NonSTsegment elevation myocardial infarction during the past 3 months (at time of randomization) Women who are pregnant or of childbearing age and not using medically acceptable effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Iron Deficiency</keyword>
	<keyword>Anemia</keyword>
	<keyword>Ferric Carboxymaltose</keyword>
</DOC>